Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 30, 2017
Eisai Inc., the U.S. subsidiary of Tokyo, Japan-based Eisai Co., Ltd., announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research...
-
May 18, 2017- Full results of Study 304, a Phase 3 study evaluating the safety and efficacy of Lenvima® (lenvatinib) as compared to sorafenib in the first-line treatment of patients with unresectable hepatocellular carcinoma, to be presented in an oral presentation on Sunday, June 4 at 8:12 a.m. CDT
Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – 7 in Chicago. The data to be presented...
-
Apr 27, 2017Data to be Presented at the American Academy of Neurology "Best Of" Epilepsy Session
Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug (AED) treatment versus placebo...
-
Apr 19, 20175-YEAR ANNIVERSARY OF LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES
Eisai Inc. announced today that its parent company Tokyo, Japan-based Eisai Co., Ltd. has pledged the continuing support of its initiatives for the elimination of lymphatic filariasis (LF), a...
-
Apr 13, 2017Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual MeetingMeta-analysis on the extrapolation of adult antiepileptic drug efficacy data, including perampanel, to pediatric patients to be featured in "Best Of" oral presentation panel
Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a range of seizure types will be presented at the...
-
Mar 28, 2017Research to be presented spans four of the Company's investigational and marketed oncology therapies, both as single agents and in combination
Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual Meeting, April 1 – 5, 2017 in Washington, D.C....
Mar 23, 2017Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on...
Mar 17, 2017Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice President, Global Medical Affairs of the Oncology...
-
Jan 25, 2017
Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib...
Jan 18, 2017Accelerating Access to Health Care in Low and Lower-Middle Income CountriesEisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable...
- Jan 4, 2017
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November...
- Dec 19, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health...
Dec 12, 2016Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest data on elenbecestat (development code: E2609), its...
-
Dec 12, 2016
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in...
- Dec 5, 2016Presentations Include Analysis of Real-World Use and Post-Hoc Analysis of Long-Term Safety and Efficacy
Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES). Perampanel, marketed as FYCOMPA® CIII, is indicated as...
- Dec 5, 2016
Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of the American Epilepsy Society (AES) held from...
- Dec 1, 2016
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Rebecca Jolley as Senior Vice President Americas Commercial, Oncology Business...
-
Nov 30, 2016
Eisai Inc. announced today the presentation of new data from studies of eribulin, marketed under the brand name Halaven®, at the 2016 San Antonio Breast Cancer Symposium (SABCS). Two ongoing...
- Nov 28, 2016
Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data from the company's anti-epileptic drugs FYCOMPA®...
-
Nov 17, 2016
Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor...
- Nov 3, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin...
-
Oct 31, 2016
Eisai Inc. and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate Eisai's internally-discovered oral dual orexin...
- Oct 31, 2016
Eisai Inc. announced today that enrollment has begun in the U.S. for MISSIONAD, a Phase 3 clinical program for E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor for patients with early...
- Oct 28, 2016Trials to assess perampanel in those with Lennox-Gastaut Syndrome, a rare form of epilepsy, and in children with partial-onset seizures now enrolling patients
Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and...
-
Oct 26, 2016Two other Eisai-marketed products -- HALAVEN® (eribulin mesylate) and BELVIQ® (lorcaserin HCI) CIV -- also collect nominations
Eisai Inc. announced today that LENVIMA® (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor (TKI), has been nominated for Best Pharmaceutical Product at the 10th Annual Prix...
